Literature DB >> 14687255

Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians.

Peter A Ubel1, Christopher Jepson, David A Asch.   

Abstract

BACKGROUND: Based on a series of clinical trials showing no difference in the effectiveness or tolerability of most major classes of antihypertensive medications, the Joint National Commission on High Blood Pressure Treatment recommends that physicians prescribe beta-blockers or diuretics as initial hypertensive therapy unless there are compelling indications for another type of medication. Nevertheless, many physicians continue to favor more expensive medications like angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers as first line agents. The persistent use of these agents raises questions as to whether physicians perceive ACE inhibitors and calcium channel blockers to be better than beta-blockers and diuretics.
METHODS: We surveyed 1,200 primary care physicians in 1997, and another 500 primary care physicians in 2000, and asked them to estimate the relative effectiveness and side effects of 4 classes of medication in treating a hypothetical patient with uncomplicated hypertension: ACE inhibitors, beta-blockers, calcium channel blockers, and diuretics. In addition, we asked them to indicate whether they ever provided free samples of hypertension medications to their patients.
RESULTS: Perceptions of the relative effectiveness and side effects of the 4 classes of hypertension medications did not significantly change over the 3 years, nor did prescription recommendations. Physicians perceive that diuretics are less effective at lowering blood pressure than the other 3 classes (P <.001). They also perceive that beta-blockers are less tolerated than the other 3 classes (P <.001). In a multivariate model, perceptions of effectiveness and tolerability displayed significant associations with prescription preference independent of background variables. The only other variable to contribute significantly to the model was provision of free medication samples to patients.
CONCLUSIONS: Despite numerous clinical trials showing no difference in the effectiveness or side-effect profiles of these 4 classes of drugs, most physicians believed that diuretics were less effective and beta-blockers were less tolerated than other medications. Moreover, their prescription practices were associated with their provision of free samples provided by pharmaceutical representatives, even after adjusting for other demographic characteristics. Efforts to increase physicians' prescribing of beta-blockers and diuretics may need to be directed at overcoming misunderstandings about the effectiveness and tolerability of these medicines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14687255      PMCID: PMC1494961          DOI: 10.1111/j.1525-1497.2003.20414.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  23 in total

1.  Changes in drug prescribing patterns related to commercial company funding of continuing medical education.

Authors:  M A Bowman; D L Pearle
Journal:  J Contin Educ Health Prof       Date:  1988       Impact factor: 1.355

2.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

3.  Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. NICS-EH Study Group. National Intervention Cooperative Study in Elderly Hypertensives.

Authors:  T Ogihara; K Kuramoto
Journal:  Hypertens Res       Date:  2000-01       Impact factor: 3.872

4.  The role of commercial sources in the adoption of a new drug.

Authors:  M Y Peay; E R Peay
Journal:  Soc Sci Med       Date:  1988       Impact factor: 4.634

5.  Scientific versus commercial sources of influence on the prescribing behavior of physicians.

Authors:  J Avorn; M Chen; R Hartley
Journal:  Am J Med       Date:  1982-07       Impact factor: 4.965

6.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

Authors:  M J Brown; C R Palmer; A Castaigne; P W de Leeuw; G Mancia; T Rosenthal; L M Ruilope
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

7.  Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.

Authors:  L Hansson; T Hedner; P Lund-Johansen; S E Kjeldsen; L H Lindholm; J O Syvertsen; J Lanke; U de Faire; B Dahlöf; B E Karlberg
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

8.  A physician survey of the effect of drug sample availability on physicians' behavior.

Authors:  L D Chew; T S O'Young; T K Hazlet; K A Bradley; C Maynard; D S Lessler
Journal:  J Gen Intern Med       Date:  2000-07       Impact factor: 5.128

9.  Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality.

Authors:  J W Peabody; J Luck; P Glassman; T R Dresselhaus; M Lee
Journal:  JAMA       Date:  2000-04-05       Impact factor: 56.272

10.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

View more
  12 in total

1.  Understanding and modifying physician behavior for prevention and management of cardiovascular disease.

Authors:  Paul A Heidenreich
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

2.  The continuing evolution of women's health.

Authors:  Marilyn M Schapira; Joan Neuner
Journal:  J Gen Intern Med       Date:  2004-07       Impact factor: 5.128

3.  Meta-analysis: impact of drug class on adherence to antihypertensives.

Authors:  Ian M Kronish; Mark Woodward; Ziad Sergie; Gbenga Ogedegbe; Louise Falzon; Devin M Mann
Journal:  Circulation       Date:  2011-04-04       Impact factor: 29.690

Review 4.  Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence.

Authors:  Janet B McGill
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

5.  Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.

Authors:  Katrina Abuabara; Joy Wan; Andrea B Troxel; Daniel B Shin; Abby S Van Voorhees; Bruce F Bebo; Gerald G Krueger; Kristina Callis Duffin; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2012-08-19       Impact factor: 11.527

6.  Clinical and nonclinical correlates of adherence to prescribing guidelines for hypertension in a large managed care organization.

Authors:  Philip C Skelding; Sumit R Majumdar; Ken Kleinman; Cheryl Warner; Susanne Salem-Schatz; Irina Miroshnik; Lisa Prosser; Steven R Simon
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-06       Impact factor: 3.738

7.  What differentiates primary care physicians who predominantly prescribe diuretics for treating mild to moderate hypertension from those who do not? A comparative qualitative study.

Authors:  Christian M Rochefort; Julia Morlec; Robyn M Tamblyn
Journal:  BMC Fam Pract       Date:  2012-02-29       Impact factor: 2.497

8.  Neighborhood socioeconomic status, Medicaid coverage and medical management of myocardial infarction: atherosclerosis risk in communities (ARIC) community surveillance.

Authors:  Randi E Foraker; Kathryn M Rose; Eric A Whitsel; Chirayath M Suchindran; Joy L Wood; Wayne D Rosamond
Journal:  BMC Public Health       Date:  2010-10-21       Impact factor: 3.295

9.  Is patients' insurance coverage associated with prescribing after hospitalization for severe, poorly controlled hypertension?

Authors:  Sydney Morss Dy; Michael J Klag; J Hunter Young
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-09       Impact factor: 3.738

10.  Patient and provider perceptions of hypertension treatment: do they agree?

Authors:  Peter J Kaboli; Daniel M Shivapour; Michael S Henderson; Mitchell J Barnett; Areef Ishani; Barry L Carter
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-06       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.